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Abstract
Over  diagnosis  of  acute  rheumatic  fever
(ARF) based on a raised antistreptolysin O titer
(ASOT) is not uncommon in endemic areas. In
this study, 660 children (aged 9.2 ±1.7 years)
were recruited consecutively and classified as:
G1 (control group, n=200 healthy children), G2
(n=20  with  ARF  1st attack),  G3  (n=40  with
recurrent  ARF),  G4  (n=100  with  rheumatic
heart disease (RHD) on long acting penicillin
(LAP)), G5 (n=100 with acute follicular tonsilli-
tis), and G6 (n=200 healthy children with histo-
ry  of  repeated  follicular  tonsillitis  more  than
three times a year). Serum ASOT was measured
by latex agglutination. Upper limit of normal
(ULN) ASOT (80th percentile) was 400 IU in G1,
200 IU in G4, and 1600 IU in G6. Significantly
high levels were seen in ARF 1st attack when
compared  to  groups  1  and  5  (P<0.001  and
P<0.05,  respectively).  ASOT  was  significantly
high in children over ten years of age, during
winter and in those with acute rheumatic cardi-
tis. ASOT showed significant direct correlation
with  the  number  of  attacks  of  tonsillitis
(P<0.05).  Egyptian  children  have  high  ULN
ASOT reaching 400 IU. This has to be taken into
consideration when interpreting its values in
suspected ARF. A rise in ASOT is less prominent
in recurrent ARF compared to 1st attack, and
acute and recurrent tonsillitis. Basal levels of
ASOT  increase  with  age  but  the  pattern  of
increase during infection is not age dependent.
Introduction
Although acute rheumatic fever (ARF) is rel-
atively rare in developed economies, it is much
more  common  in  the  developing  world  and
among  aboriginal  populations.1 It  has  been
estimated that worldwide 15.6 million people
have  RHD.2 Regions  of  major  public  health
concern include the Middle East, the Indian
subcontinent,  and  some  areas  of  Africa  and
South America.3 The prevalence of RHD was
reported to be 5.1 per 1000 in school children
in Egypt.4 In addition, the course of ARF was
found to be severe and aggressive in different
parts of the country where rheumatic fever is
still one of Egypt’s major public health prob-
lems.5,6
Evidence  of  a  host  immune  response  to
group A β hemolytic streptococcal throat infec-
tion (GAβHS) is required to confirm the diag-
nosis of rheumatic fever.7,8 Although ASOT has
been used to diagnose recent infection, inter-
pretative criteria suggested by manufacturers
of commercial antibody test kits are not suit-
able for children. It is not uncommon for labo-
ratory personnel and physicians to misinter-
pret streptococcal antibody titers because of a
failure to appreciate that the normal levels of
these antibodies are higher among school-age
children than among adults.9 Moreover, it is
often not feasible to obtain acute and convales-
cent sera. Thus, the absolute value of ASO is of
diagnostic importance.10
Upper limit of normal (ULN) values of ASOT
are known to vary also with respect to different
geographical  locations,  season,  and  site  of
infection. (11,12) Since over diagnosis of ARF
based on a raised ASOT is not uncommon, the
ULN  value  of  ASO  in  normal  children  is  of
importance to interpret ASO titers in patients
suspected to have ARF.
This study aimed to determine ASOT in nor-
mal children and in those with rheumatic fever
and tonsillitis. The variation of ASOT with age
and season was also studied.
Materials and Methods
This is a cross-sectional case control study
conducted on 660 patients chosen consecutive-
ly from the Children’s Hospital and Pediatric
Cardiology  clinic,  Ain  Shams  University
Hospital, a tertiary referral center in Cairo. 
Subjects were classified into six groups.
Group  1:  200  apparently  healthy  children
with  no  history  of  recent  tonsillitis  or  sore
throat served as a control group;
Group 2 (ARF): 20 cases in the 1st attack of
ARF, diagnosed according to updated modified
Jones criteria;8
Group  3  (recurrent  RF):  40  patients  with
recurrent ARF, diagnosed according to updated
modified Jones criteria for recurrent rheumat-
ic fever.8,13They were non compliant to the LAP
prophylaxis;
Group 4 (chronic RHD): 100 patients with
chronic RHD, all of whom had mitral regurge
with or without aortic regurge. They recieved
LAP every two weeks based on the 1992 recom-
mendations of Kassem et al.5 These patients
had no history of acute follicular tonsillitis or
rheumatic activity within three months prior
to enrollment in the study.
Group  5  (acute  follicular  tonsillitis):  100
patients with acute follicular tonsillitis. Their
inclusion criteria were: fever over 38°C, tender
anterior  cervical  lymphadenopathy,  lack  of
cough and the presence of pharyngotonsillar
exudates.14
Group 6 (history of recurrent follicular ton-
sillitis):  200  apparently  healthy  normal  chil-
dren  with  past  history  of  repeated  follicular
tonsillitis  more  than  three  times  a  year.
Children with proven attack of acute follicular
tonsillitis  within  the  three  months  before
enrollment in the study were excluded. 
Each  group  was  sub-classified  into  three
subgroups according to age: ≤5, 6-10 and ≥10
years. They were also classified according to
the season of enrollment into the study: win-
ter, spring, summer, and autumn. A full history
was  taken  of  all  study  subjects  and  they  all
underwent clinical examination with a partic-
ular emphasis on the presence of acute tonsil-
lar  inflammation,  the  number  of  attacks  of
acute follicular tonsillitis per year, criteria of
rheumatic activity and RHD. 
Blood  specimens  were  collected  by
venipuncture  from  all  subjects  and  used  for
ASOT measurement by rapid latex agglutina-
tion intended for semi quantitative determina-
tion of ASOT in serum using Avitex ASO test
kit. Avitex ASO latex particles are coated with
purified  and  stabilized  streptolysin-O.  When
the latex suspension is mixed with serum con-
taining elevated levels of ASO antibodies on a
slide, clear agglutination is seen within 2 min.
This test has been calibrated to WHO ASO First
International  Standard  Preparation  97/662.
Isotonic saline serial dilutions of patients’ sera
were prepared (1/2, 1/4, 1/8, 1/16, 1/32, etc.).
The serum ASO concentration could then be
calculated  approximately  by  multiplying  the
dilution factor (i.e. 2, 4, 8 or 16) by the detec-
tion limit. Kit controls were tested with each
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test run. Sera having titers between 200 lU/mL
and  3500  lU/mL  were  reactive.  This  method
was chosen because it is the widely used tech-
nique for ASOT measurement in Egypt.
The study was explained to the parents of
the patients, written consent was given before
enrollment, and the study was approved by the
institutional ethical committee.
Statistical analysis
Upper limit of normal ASOT was calculated
in groups without recent streptococcal infec-
tion (G1, 4 and 6) as the value exceeded by
20%  of  the  studied  population  (80th per-
centile).12 ASOT values were positively skewed
and so the raw data were log-transformed prior
to  using  the  statistical  test,  and  the  results
were presented as geometric means and 95%
confidence intervals. ANOVA (analysis of vari-
ance) was used to test the difference about
mean values of ASOT among the six groups, in
different  seasons  and  in  different  presenta-
tions of patients with acute rheumatic fever.
Multiple comparisons between pairs of groups
were  performed  using  Bonferroni  test  (post
hoc range test); results were presented as geo-
metric mean (GMT) and 95% confidence inter-
vals  (CI).  To  investigate  the  relationship
between age and ASOT, Pearson’s correlation
coefficient was calculated. Data were analyzed
using SPSS (version 15). 
Results
Six hundred and sixty patients were includ-
ed in this study. The groups are shown in Table
1. The mean age and male to female percent-
age of the different groups were recorded. 
Group 1: 9.55±2.75 years (42.5-57.5%); 
Group 2: 9.35±2.06 years (60-40%); 
Group 3: 9.85±1.72 (47.5-52.5%); 
Group 4: 9.81±2.7 years (44-56%); 
Group 5: 8.42±2.8 years (44-56%); 
Group 6: 8.64±2.8 years (46%-54%).
The data of ASOT in different groups are
presented in Figure 1 and Table 1. 
ASOT values were compared between each
two studied groups as shown in Table 2. 
Data of ASOT in age-based subgroups are
shown in Table 3.
There was a statistically significant differ-
ence of ASOT between age subgroups in G1
(P<0.0001), G4 (P<0.001), and G6 (P<0.0001);
ASOT values were the highest at over ten years
of age in all subgroups. In addition, there was
a positive correlation between age and ASOT
among  subjects  of  G1(r=0.67,  P<0.0001),
G4(r=0.422,  P<0.0001)  and  G6  (r=0.606,
P<0.0001). 
The ULN ASOT of groups 1, 4 and 6 in differ-
ent seasons is presented in Figure 2. ASOT lev-
els  were  significantly  higher  in  winter  and
autumn  in  all  groups  (P<0.0001)  except  in
group 6 in which levels in different seasons
were comparable. 
ASOT reached the highest value in patients
with rheumatic carditis (GMT 1638 IU/mL, 95%
CI; 1534, 1749) with a statistically significant
difference  when  compared  with  titers  of
patients with rheumatic chorea (979.80 IU/mL,
95% CI; 675.09, 1422.03, P<0.0001) and with
rheumatic  arthritis  (1361.18  IU/mL,  95%  CI;
1207.13, 1534.88, P<0.05).
Within  group  6,  ASOT  showed  significant
direct correlation with the number of attacks of
tonsillitis (r=0.61, P<0.001) (Table 4).
Discussion
Many Authors have studied the ULN ASOT
in  different  populations.  It  was  333  Todd’s
units  in  Minnesota,  USA,15 240  IU/mL  in
another study conducted in different American
states,9 326 IU/mL in Korea,16 305 IU/mL in
Mombai,17 239 IU/mL in a different region of
India,10 200  IU/mL  in  Tanzania,18 and  200
Todd’s units in Sweden.19
Most of these values exceeded the normal
level set by laboratories which is 200 IU/mL.
The ULN in our studied control group was even
Article
Figure 1. Antistreptolysin O titer in all groups. ARF, acute rheumatic fever; RHD, rheu-
matic heart disease; H of recurrent F tonsillitis, history of recurrent follicular tonsillitis.
Figure 2. The upper limit of normal of antistreptolysin O titer in IU/mL in groups I, IV
and VI in different seasons. ARF, acute rheumatic fever; RHD, rheumatic heart disease;
H of recurrent F tonsillitis, history of recurrent follicular tonsilli[Pediatric Reports 2012; 4:e8] [page 27]
Article
Table 4. Correlation between the antistreptolysin O titer and number of attacks of tonsillitis in group 6.
ASO
N. of attacks N Mean Std. deviation FP
3 52 907.69 211.29
4 58 1137.93 316.13 8.943 <0.05
5 62 1406.45 237.38 S
6 28 1428.57 276.03
Table 1. Antistreptolysin O titer levels in the studied groups.
Groups Controls ARF Recurrent Chronic Acute follicular H of recurrent
(1st attack) RF RHD tonsillitis f. tonsillitis
ULN (80thpercentile) 400 200 1600
GM 245.09 1334.9 507.7 215.4 1133.8 1151.9
(95% CI) (229.9,261.3) (1193.3,1493.4) (430.1,599.2) (200.5,231.3) (1070.9,1200.22 (1104.5,1201.3)
ARF, acute rheumatic fever; RHD, rheumatic heart disease; H of recurrent F tonsillitis, history of recurrent follicular tonsillitis; ULN, upper limit of normal (80th percentile); GM, geometric mean; CI, confidence
interval.
Table 2. Comparison between each two groups as regards the levels of antistreptolysin O titer. 
Acute RF Recurrent RF Chronic RHD Acute f. H of recurrent
(1st attack) tonsillitis f. tonsillitis
1) Controls <0.0001 <0.0001 0.08 <0.0001 <0.0001
2) Acute RF (1stattack) <0.0001 <0.0001 >0.99 >0.99
3) Recurrent RF <0.0001 <0.0001 <0.0001
4) Chronic RHD <0.0001 <0.0001
5) Acute follicular tonsillitis <0.0001 >0.99
ARF, acute rheumatic fever; RHD, rheumatic heart disease; H of recurrent F tonsillitis, history of recurrent follicular tonsillitis. 
Table 3. Antistreptolysin O titer in age based sub-groups .
Groups <200 200 400 800 1200 1600 1800 ULN (80th
reclassified IU/mL IU/mL IU/mL IU/ml IU/mL IU/mL IU/mL percentile)
according
Controls
≤5 years=12 9(4.5%) 3(1.5%) 200
6-10 yrs=114 53(26.5%) 44(22.0%) 16(8.0%) 1(0.5%) 200
>10yrs=74 8(4.0%) 15(7.5%) 43(21.5%) 8(4.0%) 400
ARF (1stattack)
6-10 yrs=15 1(5.0%) 8(40.0%) 3(15.0%) 3(15.0%)
>10 yrs=5 1(5.0%) 1(5.0%) 3(15.0%) 
Recurrent ARF
6-10 yrs=27 5(12.5%) 12(30.0%) 8(20%) 2(5.0%)
>10 yrs=13 6 (15.0%) 6(15%) 1 (2.5%)
Chronic RHD
≤5 yrs=3 3(3.0%) <200
6-10 yrs=61 38(38.0%) 20(20.0%) 3(3%) 200
>10 yrs=36 13(13.0%) 10(10.0%) 10(10%) 3(3%) 400
Acute follicular tonsillitis
≤5 yrs=14 11(11%) 3(3%)
6-10 yrs=64 25(25%) 26(26%) 13(13%)
>10 yrs=22 4(4%) 18(18%)
H of Recurrent F tonsillitis
≤5 yrs=21 9(4.5%) 5(2.5%) 7(3.5%) 1600
6-10 yrs=134 2(1%) 44(22.0%) 46(23.0%) 42(21.0%) 1600
>10 yrs=45 10(5.0%) 16(8.0%) 19(9.5%) 1600
ARF, acute rheumatic fever; RHD, rheumatic heart disease; H of recurrent F tonsillitis, history of recurrent follicular tonsillitis; ULN, upper limit of normal; yrs, years ULN (80th percentile).[page 28] [Pediatric Reports 2012; 4:e8]
higher  reaching  400  IU/mL  owing  to  the
repeated,  frequently  untreated,  streptococcal
infection in our community. Thus, for different
populations in different geographical locations
there may be significant differences in anti-
body titers. This can be attributed to the cli-
matic  or  socioeconomic  conditions  of  each
locality.12,20
In  the  current  study  the  ULN  (80th per-
centile) of ASOT in children with history of
repeated tonsillitis (while being free of strep-
tococcal infection) was 1600 IU/mL. This was
significantly higher than the value of the con-
trol group. We expressed the value of ASOT in
terms of upper limit (80th percentile) rather
than as mean to show the highest acceptable
value  in  this  particular  group  with  previous
infection. Although the levels are high, they do
not warrant any further investigations or treat-
ment since these children are normal and had
no complaint at the time of sampling. Re-infec-
tion usually results in sustained or continu-
ously rising titers, and it is known from exper-
imental  studies  that  antibody  responses  are
more impressive on repeated exposure.12
In the RHD group, ULN and not the mean
ASOT  was  used  to  identify  the  levels  above
which we can diagnose streptococcal infection.
The ULN ASOT was lower in RHD (200 IU)
than in healthy controls (400 IU). This might
be attributed to the effect of penicillin on the
immune response to streptococci.21 But on the
other  hand,  this  does  raise  concerns  that
acceptable levels of ASOT in the normal popu-
lation can be clearly pathological in children
under  LAP.  Similarly,  Bosmanskay22 reported
an ASOT of 187 IU/mL in patients with chronic
RHD which was significantly lower than the
titer  in  the  normal  population.  The  natural
course of streptolysin response can be modi-
fied by the administration of drugs, especially
penicillin, by reducing the overall number of
responders, and influencing the magnitude of
antibody response.23
This study demonstrated a statistically sig-
nificant  difference  between  the  ASOT  in
patients with ARF 1st attack and patients with
recurrent RF. This further supports the hypoth-
esis of an altered immune response to strepto-
cocci  following  LAP  prophylaxis.  Although
recurrence of rheumatic fever is evidence of
non  compliance  to  LAP,  lower  ASOT  reflects
partial  prophylaxis  with  a  decrease  in  inci-
dence of streptococcal infection.24,25
There was a significant difference in ASOT
according  to  age  in  groups  without  recent
streptococcal  infection  (groups  1,4  and  6)
being higher in children over ten years of age
owing to the repeated exposure to streptococ-
cal infection. Such a difference was not signif-
icant in groups with recent streptococcal infec-
tion, indicating an age-dependent basal ASOT,
but  the  pattern  of  the  increase  with  acute
infection was not related to age.
The increase in the levels of ASOT with age
was  also  demonstrated  in  many  other  stud-
ies.9,10,16,19,26 In contrast, in 2005, Danchin et
al.27 found that the mean titer of ASO in chil-
dren over ten years of age (320 IU/mL) was sig-
nificantly lower than those between five and
ten years, although it was higher than those
below five years. 
In the current study, the ASOT of each group
was significantly higher in winter and autumn.
This seasonal variation was also demonstrated
in a study conducted in Tehran.28 Since strep-
tococcal pharyngitis occurs more during win-
ter, it is not surprising that streptococcal anti-
body titers are higher in this season.12
In the present cohort, there was a signifi-
cant variation in ASOT according to the type of
presentation of rheumatic activity and showed
the highest values in patients with acute cardi-
tis. This is in agreement with Machado et al.26
The high levels seen in acute rheumatic cardi-
tis may be due to the time lapse between the
streptococcal infection and the occurrence of
carditis which allows ASOT to reach its peak
level.  On  the  other  hand,  in  patients  with
chorea  by  the  time  the  choreic  movements
appeared the ASO antibodies declined owing to
the longer latency period between the strepto-
coccal infection and the clinical manifestation.
In contrast to our study, Roodpeyma and co-
workers concluded that variable clinical pre-
sentations of rheumatic fever and increasing
intensity of cardiac involvement are not relat-
ed to ASOT.29
In  conclusion,  the  ULN  ASOT  in  normal
Egyptian children is quite high, reaching up to
400 IU/mL. The rise is significant in ARF 1st
attack and acute follicular tonsillitis, but it is
less  prominent  in  recurrent  attacks  of  RF.
Therefore, an isolated high ASOT is not suffi-
cient to diagnose ARF. Basal levels of ASOT
increase with age but age does not affect the
peak level during acute streptococcal infection.
ASOT shows the highest value in winter. LAP
prophylaxis has a prominent effect on the mag-
nitude of the host immune response to strepto-
cocci as the ULN (80th percentile) of ASOT was
only 200 IU/mL in patients with chronic RHD,
and  this  should  be  taken  into  consideration
when diagnosing recurrent rheumatic activity.
A twice weekly LAP regimen was associated
with the lowest ASOT, suggesting its efficacy
in preventing streptococcal throat infection.
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